Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192176 | 0.79 | ACACB (0.45) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6192171 | 0.79 | ACACB (0.45) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6209265 | 0.76 | FOLH1 (0.33) | — | |
| SCHEMBL6211048 | 0.76 | NLRP3 (0.33) | NPC1RAB9A | |
| SCHEMBL6212275 | 0.76 | FOLH1 (0.33) | — | |
| SCHEMBL6211338 | 0.75 | POLB (0.31) | — | |
| SCHEMBL6209740 | 0.73 | SLC6A3 (0.32) | CYP3A4NPC1RAB9ASMN1; SMN2ACACB | |
| SCHEMBL6751553 | 0.73 | SLC6A3 (0.32) | CYP3A4NPC1RAB9ASMN1; SMN2ACACB | |
| SCHEMBL6214277 | 0.73 | CYP3A4 (0.33) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6212924 | 0.72 | CNR1 (0.44) | CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299365-B1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | disclosed |